geneMAP™ FLT3 D835Y Mutation Detection Kit
$472.60
1 in stock
Description
Acute Myeloid Leukemia (AML) is the most common form of leukemia in adults and FLT3 activating mutations are expected to be present in 1 in 3 people diagnosed with AML. The presence of FLT3 activating mutations in AML indicates a poor prognosis and some treatment regimens and targeted drug trials are only accessible to patients positive for the mutation. Therefore, a false negative FLT3 test result can have serious consequences for the patient. Due to the significant impact of FLT3 testing on the lives of AML patients, the geneMAP FLT3 D816V Mutation kit represents one of the most critically important biomarker tests for AML patients.
Size: 25 tests
Related products
Product description
Acute Myeloid Leukemia (AML) is the most common form of leukemia in adults and FLT3 activating mutations are expected to be present in 1 in 3 people diagnosed with AML. The presence of FLT3 activating mutations in AML indicates a poor prognosis and some treatment regimens and targeted drug trials are only accessible to patients positive for the mutation. Therefore, a false negative FLT3 test result can have serious consequences for the patient. Due to the significant impact of FLT3 testing on the lives of AML patients, the geneMAP FLT3 D816V Mutation kit represents one of the most critically important biomarker tests for AML patients.
Size: 25 tests
Features
- FLT3 D835Y Mutation Detection
- Superior analytical sensitivity and specifity with Allele Spesfic PCR.
- Fast and Easy use with Multiplex Realtime PCR Technology.
- CE-IVD
- Real-time PCR
